Your last sentence Cassandra X is more like it. I feel that the fda doesn't want to deal with all the paper work THEY have to do and that could be just one reason why open label was offered. Also, I sure hope that this can help relieve some of the pressure, as you said, in the ICU's of hospitals.

Quote: " With the open label extension for Leronlimab, what may be tested is whether Leronlimab can be used to unclog ICUs. That would be a great basis for an EUA!

The FDA also probably hopes open label will slow requests for eINDs. "

GLTU

HCIT